Latest AI and machine learning research in skin cancer for healthcare professionals.
BACKGROUND AND OBJECTIVE: Renal clear cell carcinoma (ccRCC) is highly heterogeneous, with significa...
OBJECTIVE: To develop and validate a CT-based radiomics model to predict immunotherapy response in u...
Small cell lung cancer (SCLC) is a highly aggressive tumor with poor prognosis. Ferroptosis is close...
Melanoma is one of the most aggressive forms of skin cancer, with a high mortality rate when not det...
Ovarian cancer (OC) ranks among the most aggressive malignancies of the female reproductive system. ...
Ocular tumors encompass ocular surface tumors, orbital tumors, and intraocular tumors, characterized...
Drug resistance is a major challenge in cancer and infectious diseases, requiring innovative solutio...
BRAF inhibitors (BRAFi) have transformed the treatment of BRAF mutant melanoma, but inherent and acq...
Clear cell renal cell carcinoma (ccRCC) is characterized by high metastatic potential and frequent r...
NK and NKT cells act as major effector subsets across multiple immune heterogeneous cell populations...
The tumor microenvironment (TME) comprises diverse cellular components that spatially interact to fo...
BACKGROUND: Cutaneous malignant melanoma (CMM) is a highly malignant tumor that necessitates early d...
BACKGROUND: Ferroptosis plays a critical role in immune regulation and tumor microenvironment remode...
Systemic lupus erythematosus (SLE) is a heterogeneous autoimmune disorder in which aberrant B-cell a...
OBJECTIVES: Skin cancer is the most common malignancy in the United States, with more than five mill...
INTRODUCTION/AIMS: Myasthenia gravis (MG) is associated with thymic neoplasms. However, an increased...
PURPOSE: Cancer treatments such as chemotherapy, targeted therapy, and immunotherapy can effectively...
The interaction between autophagy and ferroptosis has resulted in the identification of novel approa...
PURPOSE: Personalized immunotherapy strategies are urgently needed for patients with locoregionally ...
BACKGROUND: Clinical decision-making for cancer immunotherapy is challenged by the heterogeneous and...
BACKGROUND: Lentigo maligna (LM) and lentigo maligna melanoma (LMM) are difficult to manage because ...